1. Sung H, Ferlay J, Siegel R et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249.
2.
Cibula D, Pötter R, Planchamp F et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol 2018; 127: 404-416.
3.
Han K, Milosevic M, Fyles A et al. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys 2013; 87: 111-119.
4.
Gill BS, Lin JF, Krivak TC et al. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements. Int J Radiat Oncol Biol Phys 2014; 90: 1083-1090.
5.
Haie-Meder C, Pötter R, Van Limbergen E et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005; 74: 235-245.
6.
Pötter R, Haie-Meder C, Van Limbergen E et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006; 78: 67-77.
7.
Mazeron R, Castelnau-Marchand P, Dumas I et al. Impact of treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemoradiation and image-guided pulsed-dose rate adaptive brachytherapy. Radiother Oncol 2015; 114: 257-263.
8.
Tanderup K, Fokdal LU, Sturdza A et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother Oncol 2016; 120: 441-446.
9.
Georg P, Pötter R, Georg D et al. Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys 2012; 82: 653-657.
10.
Kirchheiner K, Nout RA, Lindegaard JC et al. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiother Oncol 2016; 118: 160-166.
11.
Dimopoulos JC, Pötter R, Lang S et al. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol 2009; 93: 311-315.
12.
Dyk P, Jiang N, Sun B et al. Cervical gross tumor volume dose predicts local control using magnetic resonance imaging/diffusion-weighted imaging-guided high-dose-rate and positron emission tomography/computed tomography-guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 2014; 90: 794-801.
13.
Mazeron R, Castelnau-Marchand P, Escande A et al. Tumor dose-volume response in image-guided adaptive brachytherapy for cervical cancer: A meta-regression analysis. Brachytherapy 2016; 15: 537-542.
14.
Tanderup K, Fokdal LU, Sturdza A et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother Oncol 2016; 120: 441-446.
15.
Zhang N, Tang Y, Guo X et al. Analysis of dose-effect relationship between DVH parameters and clinical prognosis of definitive radio(chemo)therapy combined with intracavitary/interstitial brachytherapy in patients with locally advanced cervical cancer: A single-center retrospective study. Brachytherapy 2020; 19: 194-200.
16.
Tang X, Mu X, Zhao Z et al. Dose-effect response in image-guided adaptive brachytherapy for cervical cancer: A systematic review and meta-regression analysis. Brachytherapy 2020; 19: 438-446.
17.
Li F, Lu S, Zhao H et al. Three-dimensional image-guided combined intracavitary and interstitial high-dose-rate brachytherapy in cervical cancer: A systematic review. Brachytherapy 2021; 20: 85-94.
18.
Ke T, Wang J, Zhang N et al. Dose-effect relationship between dose-volume parameters of residual gross tumor volume and clinical prognosis in MRI-guided adaptive brachytherapy for locally advanced cervical cancer: a single-center retrospective study. Strahlenther Onkol 2023; 199: 131-140.
19.
Li F, Shi D, Bu M et al. Four-dimensional image-guided adaptive brachytherapy for cervical cancer: A systematic review and meta-regression analysis. Front Oncol 2022; 12: 870570.
20.
Schmid MP, Lindegaard JC, Mahantshetty U et al. Risk factors for local failure following chemoradiation and magnetic resonance image-guided brachytherapy in locally advanced cervical cancer: Results from the EMBRACE-I study. J Clin Oncol 2023; 41: 1933-1942.
21.
Clark BG, Souhami L, Roman TN et al. The prediction of late rectal complications in patients treated with high dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1997; 38: 989-993.
22.
Sakata K, Nagakura H, Oouchi A et al. High-dose-rate intracavitary brachytherapy: results of analyses of late rectal complications. Int J Radiat Oncol Biol Phys 2002; 54: 1369-1376.
23.
Koom WS, Sohn DK, Kim JY et al. Computed tomography-based high-dose-rate intracavitary brachytherapy for uterine cervical cancer: preliminary demonstration of correlation between dose-volume parameters and rectal mucosal changes observed by flexible sigmoidoscopy. Int J Radiat Oncol Biol Phys 2007; 68: 1446-1454.
24.
Georg P, Kirisits C, Goldner G et al. Correlation of dose-volume parameters, endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI-based brachytherapy. Radiother Oncol 2009; 91: 173-180.
25.
Kim TH, Kim JY, Sohn DK et al. A prospective observational study with dose volume parameters predicting rectosigmoidoscopic findings and late rectosigmoid bleeding in patients with uterine cervical cancer treated by definitive radiotherapy. Radiat Oncol 2013; 8: 28.
26.
Mazeron R, Maroun P, Castelnau-Marchand P et al. Pulsed-dose rate image-guided adaptive brachytherapy in cervical cancer: Dose-volume effect relationships for the rectum and bladder. Radiother Oncol 2015; 116: 226-232.
27.
Mazeron R, Dumas I, Rivin E et al. D2cm³/DICRU ratio as a surrogate of bladder hotspots localizations during image-guided adaptive brachytherapy for cervical cancer: assessment and implications in late urinary morbidity analysis. Brachytherapy 2015; 14: 300-307.
28.
Mazeron R, Fokdal LU, Kirchheiner K et al. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. Radiother Oncol 2016; 120: 412-419.
29.
Zhou YC, Zhao LN, Wang N et al. Late rectal toxicity determined by dose-volume parameters in computed tomography-based brachytherapy for locally advanced cervical cancer. Cancer Med 2016; 5: 434-441.
30.
Kirchheiner K, Nout RA, Lindegaard JC et al. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiother Oncol 2016; 118: 160-166.
31.
Ujaimi R, Milosevic M, Fyles A et al. Intermediate dose-volume parameters and the development of late rectal toxicity after MRI-guided brachytherapy for locally advanced cervix cancer. Brachytherapy 2017; 16: 968-975.
32.
Jensen NBK, Pötter R, Spampinato S, et al. Dose-volume effects and risk factors for late diarrhea in cervix cancer patients after radiochemotherapy with image guided adaptive brachytherapy in the EMBRACE I Study. Int J Radiat Oncol Biol Phys 2021; 109: 688-700.
33.
Rodriguez-Lopez JL, Ling DC, Keller A et al. Ureteral stenosis after 3D MRI-based brachytherapy for cervical cancer – Have we identified all the risk factors? Radiother Oncol 2021; 155: 86-92.
34.
Spampinato S, Fokdal LU, Pötter R et al. Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. Radiother Oncol 2021; 158: 312-320.
35.
Zhang N, Liu Y, Han D et al. The relationship between late morbidity and dose-volume parameter of rectum in combined intracavitary/interstitial cervix cancer brachytherapy: A mono-institutional experience. Front Oncol 2021; 11: 693864.
36.
Dankulchai P, Harn-Utairasmee P, Prasartseree T et al. Vaginal 11-point and volumetric dose related to late vaginal complications in patients with cervical cancer treated with external beam radiotherapy and image-guided adaptive brachytherapy. Radiother Oncol 2022; 174: 77-86.
37.
Wang J, Zhang KS, Liu Z et al. Using new vaginal doses evaluation system to assess the dose-effect relationship for vaginal stenosis after definitive radio(chemo)therapy for cervical cancer. Front Oncol 2022; 12: 840144.
38.
Westerveld H, Kirchheiner K, Nout RA et al. Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: An EMBRACE-I sub-study. Radiother Oncol 2022; 168: 8-15.
39.
Pötter R, Tanderup K, Kirisits C et al. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol 2018; 9: 48-60.
40.
Sturdza AE, Pötter R, Kossmeier M et al. Nomogram predicting overall survival in patients with locally advanced cervical cancer treated with radiochemotherapy including image-guided brachytherapy: A retro-EMBRACE study. Int J Radiat Oncol Biol Phys 2021; 111: 168-177.
41.
Westerveld H, Pötter R, Berger D et al. Vaginal dose point reporting in cervical cancer patients treated with combined 2D/3D external beam radiotherapy and 2D/3D brachytherapy. Radiother Oncol 2013; 107: 99-105.
42.
Hu K, Wang W, Liu X et al. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy. Radiother Oncol 2018; 13: 249.
